

Fig. 1 ACA Activity Effect of Serum vs Fish Gelatin




FIGURE 1




FIGURE 2





FIGURE 3

Serum Crossreactivity of ACA 6501-5A12 Peptide




FIGURE 4

Serum Crossreactivity of ACA 6626-4D3 Peptide




FIGURE 5




FIGURE 6

FIGURE 7

6501 G-Track of Random Clones

2nd Round 3rd Round 4th Round 5th Round c1c2




FIGURE 8

6635 Phage Capture ELISA with HRP- α M13 10.26.94




FIGURE 9

Phage ELISA w/ 6501 Mollif Phage 11.9.93




FIGURE 10

200710141844007

20070444001

Inhibition of (3B10)4 / 6501 Derived by 6501
Derived Peptide Monomer with 400 Diluted
Ser.6501




FIGURE 11

Inhibition of Cdl-2.3%Hu Ser.(no IgG) by
 Modified Peptides 3G3 with 400x Diluted
 Serum 6501




FIGURE 12

Inhibition of (3B10)4 / 6501 Derived by Truncated or Non-Truncated 3B10 with 400 Diluted Serum 6501





FIGURE 13

2007041111001
Inhibition of (3B10)4 / 6501 Derived by Alpha MeP 3B10
Monomer with 400 Diluted Serum 6501



---o--- 726 = AGMePCLLAPDRCPG = 2.25ug inhibited 50% ser.6501
 ---o--- 727 = AGPCLLAMePDRCPG = 0.125ug inhibited 50% ser.6501
 ---o--- 728 = AGMePCLLAMePDRCPG = 0.625ug inhibited 50% ser.6501
 ---o--- 3B10 = AGPCLLAPDRCPG = 0.5ug inhibited 50% ser.6501

* no peptide

● blank


— 50% inhibition

FIGURE 14

200710-44844001

Cross reactivity of peptide LJP 688 with aff-ACA

Cardiolipin/ β 2-GPI-coated plates




LJP

Affinity-purified ACA Number

1.0 mg/mL peptide

FIGURE 15


LJP 685-MTU-DABA-PEG (COMPOUND 36)



Treatment groups. Concentration of tolerogen in dish. * P=0.0001

Figure 16

LJP 685-ATU-MTU-AHAB-TEG (COMPOUND 35)



Treatment groups. Concentration of tolerogen in dish. * P=0.0001

Figure 17

DS-G3C Solution Structure

CLGVLA^KLC




Figure 18

Solution Structures of Lead ACA Peptides: Cyclic Nine Residue Peptides





Figure 19

Pharmacophore for binding to anti-cardiolipin antibodies, based on solution structure of DS3G3c (CLGVLA^KLC) and alanine scanning of this peptide

Amino or other positively charged group



$$D(1,2) = 22^\circ$$

Gem-dimethyl or other small hydrophobic group



6.0 Å

164°

116°

1.7 Å

4.9 Å

Figure 20A




Figure 20B

200704040001-01002

Inhibition of β_2 GP-1 by 6501-Derived Peptides with 350x Diluted Serum 6501




FIGURE 21

6701 Titration of CB2*-F:
(FITC)-GPCILLARDRCG-CO₂⁻




FIGURE 22

6501 Titration of CB2*-F:
(FITC)-GPCILLARDRCG-CO₂⁻




FIGURE 23

6501 Titration of CB2*-F:
(FITC)-GPCILLARDRCG-CO₂⁻




FIGURE 24

Displacement of CB2*-F from
6701 using 1.04 eq. of CB2*:
GPCILLARDRCG-CO₂⁻




FIGURE 25

CB2* Titration of CB2*-F/6701:
CB2*: GPCILLARDRCG-CO₂⁻




FIGURE 26

3B10 Titration of CB2*-F/6701:
3B10: AGPCLLLAPDRCPG-CO₂⁻




FIGURE 27




FIGURE 28




FIGURE 29




FIGURE 30




FIGURE 31




FIGURE 32